Jump to content

KEYLYNK-012 Study


Recommended Posts

Visit  https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04380636 or call 888-577-8839 for more  information

KEYLYNK-012 - A study of Pembrolizumab with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparib in stage III  non-small cell lung cancer (NSCLC). (NCT04380636) You may be able to join this study if you have NSCLC and:

·         Your tumor is found in the lung and structures in the middle of the chest

·         Your tumor has not spread to other parts of your body

·         Your tumor cannot be taken out by surgery

You will have an equal chance of being placed into 1 of 3 groups. The group that you are placed in will determine which study drugs you will get:

Group A: Pembro with chemotherapy and radiation followed by pembro and olaparib placebo (this is a look alike to olaparib with no active ingredients)

Group B: Pembro with chemotherapy and radiation followed by pembro and olaparib

Group 😄 Chemotherapy and radiation followed by durvalumab

You, your trial doctor, and the trial staff won’t know what drug you are getting. In case of a health emergency, they can find out.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.